

ROCHE BIOSCIENCE PAT

ID:6508555322

RECEIVED

CENTRAL FAX CENTER

JUL 14 2004

14:29 No.001 P.01

OFFICIAL

JUL 14 2004

PTO/SB/07 (06-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

To: Customer Service Center
Fax Number: (703) 872-9307


Attn: Examiner Laura Stockton Group Art Unit: 1626

From: Robert C. Hall
Roche Palo Alto LLC,
3431 Hillview Ave., Palo Alto, CA
Return Fax No.: 650/ 855-5322

Total Pages: 25 (including cover)

Certificate of Transmission under 37 CFR 1.8

I hereby certify that the correspondence cited below is being
facsimile transmitted to the Patent and Trademark Office
on July 14, 2004



Robert C. Hall

[Note: Each paper must have its own certificate of transmission, or this
certificate must identify each submitted paper.]

Documents Attached:

For: S/N 10/045,903, filed January 11, 2002, Docket No. R0038G-DIV
inventors David Goldstein, et al.

1. Request for Continued Examination Transmittal
2. Amendment, 21 pages
3. Petition for Extension of Time
4. Fee Transmittal

Doc 120000

PTO/SB/30 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Address to Commissioner for Patents
Box RCE
Alexandria, VA 22313

<i>Application Number</i>	10/045,903
<i>Filing Date</i>	January 11, 2002
<i>Examiner Name</i>	Laura Stockton
<i>First Named Inventor</i>	David Michael Goldstein
<i>Group Art Unit</i>	1626
<i>Attorney Docket Number</i>	R0038G-DIV

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

a. Previously submitted

- Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____ (Any unentered amendment(s) referred to above will be entered).
- Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- Other _____

b. Enclosed

- Preliminary Amendment
- Affidavit(s)/Declaration(s)
- Information Disclosure Statement (IDS)
- Other _____

2. Miscellaneous

a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)

b. Other _____

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.


a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. **18-1700 (see attached Fees Transmittal)**

- RCE fee required under 37 C.F.R. § 1.17(e)
- Extension of time fee (37 C.F.R. §§ 1.136 and 1.17).
- Other _____

b. Check in the amount of \$ _____ enclosed

c. Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print /Type)	Robert C. Hall	Registration No. (Attorney/Agent)	39,209
Signature		Date	July 14, 2004

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the U.S. Patent and Trademark Office on the date shown below, at (703) 672-9307.

Name (Print /Type)	Robert C. Hall	Date	July 14, 2004
Signature			

125312

PTO/SB/22 (08-03)

Approved for use through 7/31/2000. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional) R0038G-DIV								
<table border="1"> <tr> <td colspan="2">In re Application of: David Michael Goldstein, et al.</td> </tr> <tr> <td colspan="2">Application Number: 10/045,903 Filed: January 11, 2002</td> </tr> <tr> <td colspan="2">For: Pyrazole Derivatives - p38 Map Kinase Inhibitors</td> </tr> <tr> <td>Art Unit: 1626</td> <td>Examiner: Laura Stockton</td> </tr> </table>			In re Application of: David Michael Goldstein, et al.		Application Number: 10/045,903 Filed: January 11, 2002		For: Pyrazole Derivatives - p38 Map Kinase Inhibitors		Art Unit: 1626	Examiner: Laura Stockton
In re Application of: David Michael Goldstein, et al.										
Application Number: 10/045,903 Filed: January 11, 2002										
For: Pyrazole Derivatives - p38 Map Kinase Inhibitors										
Art Unit: 1626	Examiner: Laura Stockton									

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

<input checked="" type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$110.00
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ _____.	
<input type="checkbox"/> A check in the amount of the fee is enclosed.	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.	
<input checked="" type="checkbox"/> The Director has already been authorized to charge fees in this application to Deposit Account No. 18-1700. Please see Fee Transmittal accompanying this Petition.	
<input type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number _____. I have enclosed a duplicate copy of this sheet.	

I am the applicant/inventor.

assignee of record of the entire interest. See 37 CFR 3.71

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

attorney or agent of record. Registration Number 46,585

attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a). _____.


WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

July 14, 2004

Date

(650) 354-7540

Telephone Number



Signature

Robert C. Hall

(Typed or printed name)

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of _____ form(s) are submitted.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. # 125314